Hantz Financial Services Inc. Increases Stock Position in Haleon plc (NYSE:HLN)

Hantz Financial Services Inc. lifted its stake in Haleon plc (NYSE:HLN) by 1.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 422,931 shares of the company’s stock after purchasing an additional 4,180 shares during the period. Hantz Financial Services Inc.’s holdings in Haleon were worth $4,475,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Fortitude Family Office LLC bought a new stake in shares of Haleon during the 3rd quarter valued at about $28,000. Cultivar Capital Inc. bought a new stake in shares of Haleon during the 2nd quarter valued at about $40,000. Hexagon Capital Partners LLC boosted its stake in shares of Haleon by 66.6% during the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after purchasing an additional 2,677 shares in the last quarter. Prospera Private Wealth LLC bought a new stake in shares of Haleon during the 3rd quarter valued at about $57,000. Finally, BOKF NA boosted its stake in shares of Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after purchasing an additional 2,842 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Trading Down 0.7 %

Shares of NYSE HLN opened at $9.66 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The stock has a market cap of $43.71 billion, a P/E ratio of 28.40, a price-to-earnings-growth ratio of 2.94 and a beta of 0.30. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The firm has a 50-day moving average of $9.94 and a 200 day moving average of $9.41.

Analysts Set New Price Targets

HLN has been the topic of a number of research reports. The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Berenberg Bank initiated coverage on shares of Haleon in a research report on Tuesday, August 6th. They set a “buy” rating for the company. UBS Group raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, Morgan Stanley lifted their price target on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.